BRPI0620229B8 - formulações farmaceuticas e processos de produção da ditas formulações - Google Patents

formulações farmaceuticas e processos de produção da ditas formulações

Info

Publication number
BRPI0620229B8
BRPI0620229B8 BRPI0620229A BRPI0620229A BRPI0620229B8 BR PI0620229 B8 BRPI0620229 B8 BR PI0620229B8 BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 B8 BRPI0620229 B8 BR PI0620229B8
Authority
BR
Brazil
Prior art keywords
formulations
production processes
pharmaceutical
pharmaceutical formulations
formulation
Prior art date
Application number
BRPI0620229A
Other languages
English (en)
Inventor
Selkirk Alistair
Westwood Robert
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BRPI0620229A2 publication Critical patent/BRPI0620229A2/pt
Publication of BRPI0620229A8 publication Critical patent/BRPI0620229A8/pt
Publication of BRPI0620229B1 publication Critical patent/BRPI0620229B1/pt
Publication of BRPI0620229B8 publication Critical patent/BRPI0620229B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

formulação. a presente invenção refere-se a uma formulação farmacêutica que compreende (i) uma cápsula, e (ii) um núcleo compreendendo 2'-ciano- 2'-deóxi-n4-palmitoil-1 -(beta)-d-arabinofuranosilcitosina cristalina e um veículo líquido.
BRPI0620229A 2005-12-23 2006-12-22 formulações farmaceuticas e processos de produção da ditas formulações BRPI0620229B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0526419.7A GB0526419D0 (en) 2005-12-23 2005-12-23 Formulation
GB0526419.7 2005-12-23
PCT/GB2006/004927 WO2007072061A2 (en) 2005-12-23 2006-12-22 Crystalline pyrimidine nucleoside derivatives suspensions in capsules

Publications (4)

Publication Number Publication Date
BRPI0620229A2 BRPI0620229A2 (pt) 2011-11-01
BRPI0620229A8 BRPI0620229A8 (pt) 2018-01-02
BRPI0620229B1 BRPI0620229B1 (pt) 2020-09-15
BRPI0620229B8 true BRPI0620229B8 (pt) 2021-05-25

Family

ID=35841215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620229A BRPI0620229B8 (pt) 2005-12-23 2006-12-22 formulações farmaceuticas e processos de produção da ditas formulações

Country Status (16)

Country Link
US (1) US8497291B2 (pt)
EP (1) EP1962814B1 (pt)
JP (2) JP5443763B2 (pt)
CN (1) CN101346132B (pt)
AU (1) AU2006327951B2 (pt)
BR (1) BRPI0620229B8 (pt)
CA (1) CA2633308C (pt)
DK (1) DK1962814T3 (pt)
ES (1) ES2672106T3 (pt)
GB (1) GB0526419D0 (pt)
HU (1) HUE039368T2 (pt)
IL (1) IL192348A (pt)
PT (1) PT1962814T (pt)
RU (1) RU2428972C2 (pt)
TR (1) TR201808182T4 (pt)
WO (1) WO2007072061A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008132443A1 (en) * 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
KR101667641B1 (ko) 2008-06-09 2016-10-20 싸이클라셀 리미티드 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합
FI2431376T4 (fi) * 2009-05-15 2024-03-13 Delta Fly Pharma Inc 1-(2'-syano-2'-deoksi-beeta-D-arabinofuranosyyli)sytosiinimonohydrokloridin uusi vakaa kide
CN103037851A (zh) 2010-06-02 2013-04-10 安斯泰来德国有限公司 苯达莫司汀的口服剂型
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法
WO2013171473A1 (en) 2012-05-15 2013-11-21 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN106963742B (zh) * 2016-11-07 2021-02-23 澳门大学 中药固液胶囊及其制备方法
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
WO1992018504A1 (en) * 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
KR19980073479A (ko) * 1997-03-14 1998-11-05 한스루돌프하우스, 니콜케르커 사이클로스포린-함유 연질캅셀제
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
ATE374602T1 (de) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
JP5096658B2 (ja) * 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
US20050249802A1 (en) * 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
BRPI0620229A2 (pt) 2011-11-01
HK1126412A1 (en) 2009-09-04
CN101346132A (zh) 2009-01-14
JP5443763B2 (ja) 2014-03-19
GB0526419D0 (en) 2006-02-08
PT1962814T (pt) 2018-06-22
US8497291B2 (en) 2013-07-30
IL192348A (en) 2016-02-29
AU2006327951A1 (en) 2007-06-28
CA2633308C (en) 2014-06-17
BRPI0620229A8 (pt) 2018-01-02
WO2007072061A2 (en) 2007-06-28
DK1962814T3 (en) 2018-08-06
IL192348A0 (en) 2009-08-03
RU2008130411A (ru) 2010-01-27
AU2006327951B2 (en) 2012-09-06
TR201808182T4 (tr) 2018-07-23
HUE039368T2 (hu) 2018-12-28
ES2672106T3 (es) 2018-06-12
CA2633308A1 (en) 2007-06-28
JP2009520797A (ja) 2009-05-28
BRPI0620229B1 (pt) 2020-09-15
EP1962814B1 (en) 2018-04-25
JP2013189463A (ja) 2013-09-26
RU2428972C2 (ru) 2011-09-20
WO2007072061A3 (en) 2007-10-25
US20090074856A1 (en) 2009-03-19
CN101346132B (zh) 2013-01-16
EP1962814A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
BR0207726A (pt) Sais farmacêuticos
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
BRPI0412689A (pt) derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
EP2058317A4 (en) AMINOOPHOSPHORIC ACID DERTER DERIVATIVE AND THIS ACTIVE MODULATOR OF THE S1P RECEPTOR
NI200800207A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
NI200600240A (es) FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
ECSP099776A (es) Moduladores de la gamma secretasa
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0517846A (pt) azaindolcarboxamidas
BRPI0511874A (pt) derivados da pirrolopiridina
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
BRPI0620229A8 (pt) formulação
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
NO20084478L (no) Konjugerte lipidderivater

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ESCLARECA O DEPOSITANTE A DIVERGENCIA EXISTENTE NO NOME DO INVENTOR ROBERT WESTWOOD CONSTANTE DA PUBLICACAO WO NO 2007/072061 DE 28/06/2007 E O EXISTENTE NA PETICAO INICIAL.

B25G Requested change of headquarter approved

Owner name: CYCLACEL LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: CYCLACEL LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2754 DE 17-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.